Stockscreener 앱 받기
9.40
1.29%
0.12
전일 마감가:
$9.28
열려 있는:
$9.4
하루 거래량:
2.54M
Relative Volume:
0.56
시가총액:
$546.51M
수익:
$11.13M
순이익/손실:
$-114.59M
주가수익비율:
-4.064
EPS:
-2.313
순현금흐름:
$-113.96M
1주 성능:
-1.98%
1개월 성능:
+125.42%
6개월 성능:
-63.14%
1년 성능:
+58.25%
1일 변동 폭
$9.26
$9.81
1주일 범위
$9.065
$11.00
52주 변동 폭
$2.96
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
명칭
Capricor Therapeutics Inc
전화
(310) 358-3200
주소
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
9.40 | 397.38M | 11.13M | -114.59M | -113.96M | -2.313 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-30 | 개시 | Alliance Global Partners | Buy |
| 2025-06-26 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | Roth Capital | Buy |
| 2024-10-21 | 개시 | Piper Sandler | Overweight |
| 2024-05-17 | 개시 | Oppenheimer | Outperform |
| 2024-01-05 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-26 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-26 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2017-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2017-02-13 | 재개 | Rodman & Renshaw | Buy |
| 2016-07-06 | 재개 | H.C. Wainwright | Buy |
| 2016-06-15 | 개시 | ROTH Capital | Buy |
모두보기
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
CAPR Stock Sinks As Investors Brace For Imminent FDA Call On Deramiocel - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) Healthcare Strategy Focus - Kalkine Media
Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Morningstar
CAPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Activist Investor Sounds Alarm on Capricor’s Cash Burn - TradingView
/C O R R E C T I O N — Kessler Topaz Meltzer & Check, LLP/ - Morningstar
Activist Investor Kaos Capital Demands Board Overhaul at Capricor Ahead of FDA Decision on DMD Therapy - finance.biggo.com
INVESTOR DEADLINE: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Substantial Losses Have Opportunity to Lead Capricor Class Action Lawsuit Before September 28, 2026 Deadline - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - lincolnjournal.com
Capricor Stock Faces Securities-Fraud Case as FDA Review Stays Open - TechStock²
Kaos Capital Pushes for Strategic Board Meeting at Capricor Ther - GuruFocus
Kaos Capital pushes for board changes at Capricor Therapeutics - Investing.com
Kaos Capital pushes for board changes at Capricor Therapeutics By Investing.com - Investing.com Canada
Capricor shareholder cites ~$80.2M cash drop and seeks spending cuts - Stock Titan
Kaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholders - Yahoo Finance
Duchenne Cell Therapy Shifts Its Target from the Heart to Arm Function as Decision Date Slips - Medical Daily
Shareholder pressures Capricor; Lilly dives deeper into vaccines - Yahoo Finance
Capricor (CAPR) Q2 2026 Earnings Call Transcript - AOL.com
Capricor Draws Investor Attention As Shareholder Kaos Capital Pushes For Board Shakeup Ahead Of Key FDA Decision On DMD Therapy - Stocktwits
Capricor (CAPR) Q2 2026 Earnings Call Transcript - The Motley Fool
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm to Learn About Their Legal Rights - The Globe and Mail
Deadline Alert: Capricor Therapeutics, Inc. (CAPR) - GlobeNewswire
Capricor Therapeutics (CAPR) Faces Valuation Challenges Ahead of FDA Decision - GuruFocus
Capricor Therapeutics, Inc. Investors Have Opportunity to - GlobeNewswire
CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities LawsuitContact SueWallSt - Morningstar
Capricor Therapeutics (CAPR) Faces Market Pressure Amid FDA Conc - GuruFocus
Capricor Therapeutics Shareholder Alert: ClaimsFiler - GlobeNewswire
Capricor slips on potential Deramiocel rejection (CAPR:NASDAQ) - Seeking Alpha
CAPR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesCAPR - PR Newswire
Piper Sandler Downgrades Capricor Therapeutics, Cuts Target to $2 - scanx.trade
CAPRICOR THERAPEUTICS, INC. (CAPR) SHAREHOLDER ALERT - GlobeNewswire
$Capricor Therapeutics (CAPR.US)$ FDA APPROVAL 2026-08-22 in two days get ready!!! - Moomoo
CAPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (N - The National Law Review
Capricor (CAPR) Closed 58% Higher on an FDA Lifeline. Is Approval Really Back on Track? - Yahoo Finance
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to the Lead Plaintiff Deadline on September 28, 2026 - Barchart.com
Capricor Therapeutics (CAPR): Millennium stake slips under 5% - Stock Titan
ROSEN, A LEADING NATIONAL FIRM, Encourages Capricor - GlobeNewswire
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - TMX Newsfile
CAPR EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026 - TMX Newsfile
Bronstein, Gewirtz & Grossman LLC Urges Capricor - GlobeNewswire
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Class Action Lawsuit: Investors Face September 28, 2026, Deadline - NewMediaWire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
CAPR Investor Reminder: Capricor Therapeutics Securities - GlobeNewswire
Capricor Therapeutics, Inc. Notice of September 28, 2026 - GlobeNewswire
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NewMediaWire
Robbins LLP Urges CAPR Stockholders to Contact the Firm for Information About the Class Action Against Capricor Therapeutics, Inc. - WBOC TV
CAPR INVESTOR REMINDER: Capricor Therapeutics, Inc. Investors Have Until September 28, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role - lincolnjournal.com
Kaplan Fox & Kilsheimer LLP Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before September 28, 2026 - Barchart.com
All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement – CAPR Stock Jumps 6% - Stocktwits
Capricor Therapeutics Inc (CAPR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Capricor Therapeutics Inc 주식 (CAPR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Option Exercise |
3.18 |
24,100 |
76,638 |
35,323 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 25 '26 |
Sale |
30.38 |
24,100 |
732,158 |
11,223 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
31,047 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
30,947 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
30,547 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Jun 24 '26 |
Sale |
30.00 |
400 |
12,000 |
30,547 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Option Exercise |
3.18 |
500 |
1,590 |
11,723 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 24 '26 |
Option Exercise |
3.18 |
400 |
1,272 |
11,623 |
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Jun 22 '26 |
Sale |
30.00 |
500 |
15,000 |
11,223 |
0.86%
0.31%
자본화:
|
볼륨(24시간):